Ir para o conteúdo principal

Compass Therapeutics (NASDAQ: CMPX) — Perfil da empresa, notícias e dados financeiros

Logo de Compass Therapeutics
CMPX Compass Therapeutics
Compass Therapeutics primary media
Perfil da empresa

Compass Therapeutics

Compass Therapeutics (NASDAQ:CMPX) is a biotechnology firm deeply immersed in the discovery and development of antibody therapeutics aimed at treating cancer, autoimmune disorders, and other diseases. The company leverages its proprietary StitchMabs™ and common light chain platforms to engineer novel biologic agents. Compass Therapeutics focuses on advancing its robust pipeline of therapeutic candidates, including lead assets that show promising preclinical and early clinical results for a range of medical conditions. The ultimate objective of Compass Therapeutics is to transform the landscape of treatment options available to patients suffering from severe diseases by bringing innovative and effective therapies to market.

Resumo

Public USParticipação acionária
2014Ano de fundação
32Funcionários
Boston, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
Boston, US

Produtos e/ou serviços de Compass Therapeutics

  • CTx-471, a next-generation checkpoint inhibitor designed to stimulate the immune system to target and kill cancer cells.
  • CTX-8371, a dual-action PI3K and HDAC inhibitor aimed at treating solid tumors.
  • Patient-derived xenograft (PDX) models and in-house developed tumor cell lines for predictive efficacy testing and personalized medicine research.

equipe executiva do Compass Therapeutics

  • Thomas J. SchuetzCEO & Vice Chairman
  • Barry ShinChief Financial Officer
  • Jonathan E. AndermanSenior VP, General Counsel & Corporate Secretary
  • Neil L. LernerSenior VP & Chief Accounting Officer
  • Bing GongChief Scientific Officer
  • Anna GiffordSenior Manager of Communications & Chief of Staff
  • Karin HerreraSenior VP & Head of Clinical Operations
  • James KranzVP and Head of Chemistry Manufacturing & Controls
  • Cynthia A. SirardChief Medical Officer
  • Arjun PrasadChief Commercial Officer

Últimas notícias sobre a Compass Therapeutics

Principais indicadores financeiros

Resultados divulgados pela Compass Therapeutics, em USD.

Cap. de mercado
136,9 mi
Receita (TTM)
0
P/L
—
LPA (diluído, TTM)
-0.4
Dividend yield
—
Margem de lucro
0.0%
Receita e lucro anuais da Compass Therapeutics
Fim do ano fiscalReceitaResultado operacionalLucro líquido
0-72,8 mi-66,5 mi
850 mil-56,6 mi-49,4 mi
0-50,4 mi-42,5 mi
0-41,7 mi-39,2 mi